Disparities at the major histocompatibility complex (MHC) antigens and associated minor antigens trigger harmful immune responses, leading to graft rejection after transplantation. We showed that MHC-silenced cells and tissues are efficiently protected against rejection. In complex vascularized organs, the endothelium is the major interface between donor and recipient. This study therefore aimed to reduce the immunogenicity of the lung by silencing MHC expression on the endothelium. In porcine lungs, short-hairpin RNAs targeting beta-2-microglobulin and class II-transactivator transcripts were delivered by lentiviral vectors during normothermic ex vivo perfusion to silence swine leukocyte antigen (SLA) I and II expression permanently. The results demonstrated the feasibility of genetically engineering all lung regions, achieving a targeted silencing effect for SLA I and II of 67% and 52%, respectively, without affecting cell viability or tissue integrity. This decrease in immunogenicity carries the potential to generate immunologically invisible organs to counteract the burden of rejection and immunosuppression.
Get full access to this article
View all access options for this article.
References
1.
AngaswamyN, TiriveedhiV, SarmaNJ, et al.Interplay between immune responses to HLA and non-HLA self-antigens in allograft rejection. Hum Immunol, 2013; 74:1478–1485.
2.
NathDS, BashaHI, MohanakumarT. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant, 2010; 15:16–20.
3.
WaltonDC, HihoSJ, CantwellLS, et al.HLA matching at the eplet level protects against chronic lung allograft dysfunction. Am J Transplant, 2016; 16:2695–2703.
4.
SommerW, HallenslebenM, IusF, et al.Repeated human leukocyte antigen mismatches in lung re-transplantation. Transplant Immunol, 2017; 40:1–7.
5.
McManigleW, PavliskoEN, MartinuT. Acute cellular and antibody-mediated allograft rejection. Semin Respir Crit Care Med, 2013; 34:320–335.
6.
YousemSA, ZeeviA. The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol, 2012; 36:987–992.
7.
IusF, SommerW, KienekeD, et al.IgM-enriched human intravenous immunoglobulin-based treatment of patients with early donor specific anti-HLA antibodies after lung transplantation. Transplantation, 2016; 100:2682–2692.
8.
BorgerAK, EickeD, WolfC, et al.Generation of HLA-universal iPSCs-derived megakaryocytes and platelets for survival under refractoriness conditions. Mol Med, 2016; 22:274–285.
9.
GrasC, RatusznyD, HadamitzkyC, et al.miR-145 contributes to hypertrophic scarring of the skin by inducing myofibroblast activity. Mol Med, 2015; 21:296–304.
10.
FigueiredoC, GoudevaL, HornPA, et al.Generation of HLA-deficient platelets from hematopoietic progenitor cells. Transfusion, 2010; 50:1690–1701.
11.
FigueiredoC, WedekindD, MullerT, et al.MHC universal cells survive in an allogeneic environment after incompatible transplantation. BioMed Res Int, 2013; 2013:796046.
12.
WiegmannB, FigueiredoC, GrasC, et al.Prevention of rejection of allogeneic endothelial cells in a biohybrid lung by silencing HLA-class I expression. Biomaterials, 2014; 35:8123–8133.
13.
YusenRD, EdwardsLB, KucheryavayaAY, et al.The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant, 2014; 33:1009–1024.
14.
AltonEW, SternM, FarleyR, et al.Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet, 1999; 353:947–954.
15.
ChiuchioloMJ, KaminskySM, SondhiD, et al.Intrapleural administration of an AAVrh.10 vector coding for human alpha1-antitrypsin for the treatment of alpha1-antitrypsin deficiency. Hum Gene Ther Clin Dev, 2013; 24:161–173.
16.
MossRB, RodmanD, SpencerLT, et al.Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest, 2004; 125:509–521.
17.
ConeseM, AscenzioniF, BoydAC, et al.Gene and cell therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros, 2011; 10:S114–128.
18.
LiuX, LuoM, GuoC, et al.Comparative biology of rAAV transduction in ferret, pig and human airway epithelia. Gene Ther, 2007; 14:1543–1548.
19.
CarbonaroDA, JinX, PetersenD, et al.In vivo transduction by intravenous injection of a lentiviral vector expressing human ADA into neonatal ADA gene knockout mice: a novel form of enzyme replacement therapy for ADA deficiency. Mol Ther, 2006; 13:1110–1120.
20.
AbrahimiP, LiuR, PoberJS. Blood vessels in allotransplantation. Am J Transplant, 2015; 15:1748–1754.
21.
WarneckeG, MoradiellosJ, TudoracheI, et al.Normothermic perfusion of donor lungs for preservation and assessment with the Organ Care System Lung before bilateral transplantation: a pilot study of 12 patients. Lancet, 2012; 380:1851–1858.
22.
FildesJE, ArcherLD, BlaikleyJ, et al.Clinical outcome of patients transplanted with marginal donor lungs via ex vivo lung perfusion compared to standard lung transplantation. Transplantation, 2015; 99:1078–1083.
23.
FigueiredoC, SeltsamA, BlasczykR. Class-, gene-, and group-specific HLA silencing by lentiviral shRNA delivery. J Mol Med, 2006; 84:425–437.
24.
WoodKJ, GotoR. Mechanisms of rejection: current perspectives. Transplantation, 2012; 93:1–10.
25.
ParkerDG, CosterDJ, BreretonHM, et al.Lentivirus-mediated gene transfer of interleukin 10 to the ovine and human cornea. Clin Exp Ophthalmol, 2010; 38:405–413.
26.
RyuYH, KimJC. Expression of indoleamine 2,3-dioxygenase in human corneal cells as a local immunosuppressive factor. Invest Ophthalmol Vis Sci, 2007; 48:4148–4152.
27.
YamadaY, LangnerT, InciI, et al.Impact of human leukocyte antigen mismatch on lung transplant outcome. Interact Cardiovasc Thorac Surg, 2018; 26:859–864.
28.
ThomasKA, ValenzuelaNM, ReedEF. The perfect storm: HLA antibodies, complement, FcgammaRs, and endothelium in transplant rejection. Trends Mol Med, 2015; 21:319–329.
29.
CmielewskiP, FarrowN, DevereuxS, et al.Gene therapy for cystic fibrosis: improved delivery techniques and conditioning with lysophosphatidylcholine enhance lentiviral gene transfer in mouse lung airways. Exp Lung Res, 2017; 43:426–433.
30.
LowensteinPR, MandelRJ, XiongWD, et al.Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther, 2007; 7:347–360.
31.
GugginoWB, BensonJ, SeagraveJ, et al.A preclinical study in rhesus macaques for cystic fibrosis to assess gene transfer and transduction by AAV1 and AAV5 with a dual-luciferase reporter system. Hum Gene Ther Clin Dev, 2017; 28:145–156.
32.
LoringHS, ElMallahMK, FlotteTR. Development of rAAV2-CFTR: history of the first rAAV vector product to be used in humans. Hum Gene Therapy Methods, 2016; 27:49–58.
33.
PayneJG, TakahashiA, HigginsMI, et al.Multilineage transduction of resident lung cells in vivo by AAV2/8 for alpha1-antitrypsin gene therapy. Mol Ther Methods Clin Dev, 2016; 3:16042.
34.
DengB, SunT, TangB, et al.Surgery combined with adenoviral p53 gene therapy for treatment of non-small cell lung cancer: a Phase II study. Oncotarget, 2017; 8:107089–107095.
35.
SatoJ, KonnoN, MurakamiM, et al.Adenovirus-mediated ICOSIg gene therapy in a presensitized murine model of allergic rhinitis. Adv Otorhinolaryngol, 2016; 77:59–66.
36.
Di CoccoP, BonanniL, D'AngeloM, et al.Clinical operational tolerance after solid organ transplantation. Transplant Proc, 2009; 41:1278–1282.
37.
BeckerS, SteinmeyerJ, AvsarM, et al.Evaluating acellular versus cellular perfusate composition during prolonged ex vivo lung perfusion after initial cold ischaemia for 24 hours. Transplant Int, 2016; 29:88–97.
38.
GrasC, SchulzeK, GoudevaL, et al.HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model. Hum Gene Ther, 2013; 24:1018–1028.
39.
PirenneJ, Pirenne-NoizatF, de GrooteD, et al.Cytokines and organ transplantation. A review. Nucl Med Biol, 1994; 21:545–555.
40.
PfizenmaierK, ScheurichP, SchluterC, et al.Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol, 1987; 138:975–980.
41.
LeeKS, ChunSY, LeeMG, et al.The prevention of TNF-alpha/IFN-gamma mixture-induced inflammation in human keratinocyte and atopic dermatitis-like skin lesions in Nc/Nga mice by mineral-balanced deep sea water. Biomed Pharmacother, 2018; 97:1331–1340.
42.
MehtaNN, TeagueHL, SwindellWR, et al.IFN-gamma and TNF-alpha synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep, 2017; 7:13831.
43.
OhmoriY, SchreiberRD, HamiltonTA. Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB. J Biol Chem, 1997; 272:14899–14907.
44.
HodgeG, HodgeS, ChambersD, et al.Acute lung transplant rejection is associated with localized increase in T-cell IFNgamma and TNFalpha proinflammatory cytokines in the airways. Transplantation, 2007; 84:1452–1458.
45.
MehaffeyJH, CharlesEJ, SharmaAK, et al.Ex vivo lung perfusion rehabilitates sepsis-induced lung injury. Ann Thorac Surg, 2017; 103:1723–1729.
46.
SprattJR, MattisonLM, IaizzoPA, et al.An experimental study of the recovery of injured porcine lungs with prolonged normothermic cellular ex vivo lung perfusion following donation after circulatory death. Transplant Int, 2017; 30:932–944.
47.
ItokuaKE, MakuloJR, LepiraFB, et al.Albuminuria, serum antioxidant enzyme levels and markers of hemolysis and inflammation in steady state children with sickle cell anemia. BMC Nephrol, 2016; 17:178.
48.
MuchtarE, DispenzieriA, LacyMQ, et al.Elevation of serum lactate dehydrogenase in AL amyloidosis reflects tissue damage and is an adverse prognostic marker in patients not eligible for stem cell transplantation. Br J Haematol, 2017; 178:888–895.
49.
LonatiC, BassaniGA, BrambillaD, et al.Influence of ex vivo perfusion on the biomolecular profile of rat lungs. FASEB J, 2018; 32:5532–5549.
50.
SadariaMR, SmithPD, FullertonDA, et al.Cytokine expression profile in human lungs undergoing normothermic ex-vivo lung perfusion. Ann Thorac Surg, 2011; 92:478–484.
51.
AndreassonASI, BorthwickLA, GillespieC, et al.The role of interleukin-1beta as a predictive biomarker and potential therapeutic target during clinical ex vivo lung perfusion. J Heart Lung Transplant, 2017; 36:985–995.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
